| NCT ID | NCT01974440 |
| Title | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Janssen Research & Development, LLC |
| Indications | |
| Therapies |
Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate |
| Age Groups: | adult |